0QAV.L LSE
Nanobiotix S.A.
1W: -5.5%
1M: +31.8%
3M: +77.5%
YTD: +81.7%
1Y: +1183.1%
3Y: +1004.1%
€36.70 ($42.57)
-1.50 (-3.93%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market Cap€1.8B ($2.1B)
52W Range1.624-41.5
Volume32,609
Avg Volume8,588
Beta0.58
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOLaurent Levy
Employees108
SectorHealthcare
IndustryBiotechnology
IPO Date2014-02-13
Websitenanobiotix.com
60 rue de Wattignies
Paris 75012
FR
Paris 75012
FR
33 1 40 26 04 70
About Nanobiotix S.A.
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Latest News
No recent news
Recent Insider Trades
No insider trades found